Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study

Int J Urol. 2017 Feb;24(2):151-156. doi: 10.1111/iju.13265. Epub 2016 Dec 22.

Abstract

Objective: To determine if cholesterol is a risk factor for the development of lower urinary tract symptoms in asymptomatic men.

Methods: A post-hoc analysis of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study was carried out in 2323 men with baseline International Prostate Symptom Score <8 and not taking benign prostatic hyperplasia or cholesterol medications. Cox proportion models were used to test the association between cholesterol, high-density lipoprotein, low-density lipoprotein and the cholesterol : high-density lipoprotein ratio with incident lower urinary tract symptoms, defined as first report of medical treatment, surgery or two reports of an International Prostate Symptom Score >14.

Results: A total of 253 men (10.9%) developed incident lower urinary tract symptoms. On crude analysis, higher high-density lipoprotein was associated with a decreased lower urinary tract symptoms risk (hazard ratio 0.89, P = 0.024), whereas total cholesterol and low-density lipoprotein showed no association. After multivariable adjustment, the association between high-density lipoprotein and incident lower urinary tract symptoms remained significant (hazard ratio 0.89, P = 0.044), whereas no association was observed for low-density lipoprotein (P = 0.611). There was a trend for higher cholesterol to be linked with higher lower urinary tract symptoms risk, though this was not statistically significant (hazard ratio 1.04, P = 0.054). A higher cholesterol : high-density lipoprotein ratio was associated with increased lower urinary tract symptoms risk on crude (hazard ratio 1.11, P = 0.016) and adjusted models (hazard ratio 1.12, P = 0.012).

Conclusions: Among asymptomatic men participating in the REDUCE study, higher cholesterol was associated with increased incident lower urinary tract symptoms risk, though the association was not significant. A higher cholesterol : high-density lipoprotein ratio was associated with increased incident lower urinary tract symptoms, whereas higher high-density lipoprotein was protective. These findings suggest dyslipidemia might play a role in lower urinary tract symptoms progression.

Keywords: benign prostatic hyperplasia; cholesterol; lipids; lower urinary tract symptoms.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • 5-alpha Reductase Inhibitors / therapeutic use
  • Age Factors
  • Aged
  • Asymptomatic Diseases / epidemiology
  • Cholesterol / blood*
  • Datasets as Topic
  • Disease Progression
  • Dutasteride / therapeutic use
  • Dyslipidemias / blood*
  • Dyslipidemias / complications
  • Humans
  • Incidence
  • Longitudinal Studies
  • Lower Urinary Tract Symptoms / epidemiology*
  • Lower Urinary Tract Symptoms / etiology
  • Lower Urinary Tract Symptoms / pathology
  • Male
  • Middle Aged
  • Prostatic Hyperplasia / blood*
  • Prostatic Hyperplasia / complications
  • Prostatic Hyperplasia / drug therapy
  • Prostatic Neoplasms / prevention & control
  • Risk Factors

Substances

  • 5-alpha Reductase Inhibitors
  • Cholesterol
  • Dutasteride